Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ET. Company Participants. Robin C. Kramer - Executive VP & CFO. Conference ...

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...

the offer could be viewed as a way to add a new revenue stream whilst bolstering its early-stage pipeline. Sage confirmed Biogen's "unsolicited, nonbinding proposal" in a stock exchange filing ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Real time quote data is not available at this time. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.

bDepartment of Rehabilitation Medicine, VU University Medical Centre, Amsterdam Movement Sciences and Amsterdam Neuroscience, Amsterdam, Netherlands ...